| 132.28 -1.73 (-1.29%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 156.12 |
1-year : | 160.07 |
| Resists | First : | 133.66 |
Second : | 137.05 |
| Pivot price | 133.82 |
|||
| Supports | First : | 128.19 |
Second : | 106.65 |
| MAs | MA(5) : | 134.72 |
MA(20) : | 133.56 |
| MA(100) : | 131.34  |
MA(250) : | 120.05 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 50.9 |
D(3) : | 70.1 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 141.22 | Low : | 99.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABT ] has closed above bottom band by 16.6%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 134.3 - 135.1 | 135.1 - 135.7 |
| Low: | 130.21 - 131.29 | 131.29 - 132.09 |
| Close: | 130.87 - 132.45 | 132.45 - 133.63 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Mon, 16 Jun 2025
Abbott (ABT) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Mon, 16 Jun 2025
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Sun, 15 Jun 2025
Jim Cramer Calls Abbott “Really Excellent” - Insider Monkey
Fri, 13 Jun 2025
Abbott Laboratories (ABT) Maintains Quarterly Dividend of $0.59 - GuruFocus
Thu, 12 Jun 2025
Abbott Laboratories Stock Sees RS Rating Rise To 82 - Investor's Business Daily
Wed, 11 Jun 2025
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1,740 (M) |
| Shares Float | 1,730 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 80.5 (%) |
| Shares Short | 22,260 (K) |
| Shares Short P.Month | 21,690 (K) |
| EPS | 7.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 28.05 |
| Profit Margin | 31.8 % |
| Operating Margin | 18 % |
| Return on Assets (ttm) | 6.3 % |
| Return on Equity (ttm) | 30.6 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 13.62 |
| Sales Per Share | 24.33 |
| EBITDA (p.s.) | 6.33 |
| Qtrly Earnings Growth | 8.6 % |
| Operating Cash Flow | 8,950 (M) |
| Levered Free Cash Flow | 6,030 (M) |
| PE Ratio | 17.2 |
| PEG Ratio | 0 |
| Price to Book value | 4.71 |
| Price to Sales | 5.43 |
| Price to Cash Flow | 25.71 |
| Dividend | 0.58 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|